No Data
No Data
China's assets continue to be popular! Japan's listed 500ETF rose by 115%, while the Hang Seng Index in Hong Kong once approached its recent high point.
What news stimulated the rise of semiconductor and pharmaceutical stocks in the Hong Kong stock market? What is the reason for the strong performance of petroleum stocks?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Market Cap Surged HK$570m Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (688505.SH): The first subject has been enrolled in the completion of the phase II clinical trial of injectable Hemoporfin for the treatment of fresh red nevus in the USA.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced on September 23 that the company's F0026 project, an injectable hemoporfin therapy for treating fresh red birthmarks, has successfully completed the first subject's enrollment in the phase II clinical trial in the USA. Hemoporfin is the world's first photodynamic drug for the treatment of fresh red birthmarks, integrating new drug targets, new compounds, and new indications into one. As a second-generation photosensitizer, hemoporfin has features such as stable compound structure and low phototoxicity. Its application in the treatment of fresh red birthmarks has been included in the People's Health Publishing House's textbook "Dermatology" (Ninth Edition).
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349) fell by 16.70%, currently trading at 1.750 yuan, hitting a 52-week low.
As of 11:31, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) fell 16.70% compared to the previous closing price, currently trading at 1.750 yuan, hitting a 52-week low; with a volume of 0.273 million shares and a turnover of 0.4809 million Hong Kong dollars.
FUDANZHANGJIANG: INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2024
No Data
No Data